At a glance
ClinicalIndex Comparison Record- ✓Cytologically or histologically confirmed breast cancer that is estrogen receptor or progesterone receptor positive and locally advanced and/or metastatic
- ✓Female, age ≥19 years
- ✓ECOG performance status <2
- ✓Prior response to first or second-line hormonal therapy (partial/complete response >6 months or stable disease >6 months per RECIST), now resistant to that hormone therapy, and must continue current hormone therapy
- ✕De novo (primary) resistance to hormone therapy
- ✕Brain metastases
- ✕History of thrombosis in the past year, including transient ischemic attack
- ✕Uncontrolled hypertension (>150/100 mmHg)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Metastatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial
In Brief
A Phase 2 clinical trial evaluating Avastin and Hormonal therapy for Metastatic Breast Cancer. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if acquired hormone therapy resistance can be reversed by Avastin (Bevacizumab), as measured by time to disease progression and evaluate toxicity of the combination of hormone treatment plus Avastin (Bevacizumab).
Study Details
Timeline
Interventions
All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)